Joseph L. Kim

发表

The landscape of kinase fusions in cancer

Nicolas Stransky, E. Cerami, C. Lengauer, 2014, Nature Communications.

Abstract 954: The landscape of kinase fusions in cancer

Ethan Cerami, Nicolas Stransky, Christoph Lengauer, 2015 .

Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors.

Daniel Elbaum, P. Gallant, A. Coxon, 2007, Journal of medicinal chemistry.

Discovery of triazine-benzimidazoles as selective inhibitors of mTOR.

T. Bush, A. Cheng, D. Whittington, 2011, Bioorganic & medicinal chemistry letters.

Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.

P. Gallant, A. Oliveira-dos-Santos, J. Newcomb, 2008, Journal of medicinal chemistry.

Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.

P. Gallant, A. Oliveira-dos-Santos, J. Newcomb, 2008, Journal of medicinal chemistry.

Purinylpyridinylamino-based DFG-in/αC-helix-out B-Raf inhibitors: Applying mutant versus wild-type B-Raf selectivity indices for compound profiling.

D. Whittington, H. Bregman, Matthew R. Lee, 2016, Bioorganic & medicinal chemistry.

Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity.

Xin Huang, David Powers, Daniela Metz, 2006, Journal of medicinal chemistry.

Selective inhibitors of the mutant B-Raf pathway: discovery of a potent and orally bioavailable aminoisoquinoline.

Thomas Nixey, Nick A. Paras, D. Whittington, 2009, Journal of medicinal chemistry.

Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.

S. Ou, C. Lengauer, Wei Hu, 2018, Cancer discovery.

Synthesis, structural analysis, and SAR studies of triazine derivatives as potent, selective Tie-2 inhibitors.

P. Gallant, M. Morrison, P. Rose, 2007, Bioorganic & medicinal chemistry letters.

Selective and Potent Raf Inhibitors Paradoxically Stimulate Normal Cell Proliferation and Tumor Growth

R. Radinsky, R. Kendall, K. Nagapudi, 2010, Molecular Cancer Therapeutics.

Molecular Medicine in Practice Molecular Cancer Therapeutics Selective and Potent Raf Inhibitors Paradoxically Stimulate Normal Cell Proliferation and Tumor Growth

R. Radinsky, R. Kendall, K. Nagapudi, 2010 .

First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.

Nicolas Stransky, C. Lengauer, C. Winter, 2015, Cancer discovery.

A precision therapy against cancers driven by KIT/PDGFRA mutations

A. Gardino, N. Lydon, M. Heinrich, 2017, Science Translational Medicine.

Discovery of N-phenyl nicotinamides as potent inhibitors of Kdr.

A. Coxon, T. Harvey, R. Syed, 2007, Bioorganic & medicinal chemistry letters.

Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.

Yoon-Koo Kang, K. Hoeflich, C. Lengauer, 2019, Cancer discovery.

Conformation-specific effects of Raf kinase inhibitors.

Joseph L. Kim, Xiaolun Wang, 2012, Journal of medicinal chemistry.

Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitor.

Richard Kendall, P. Gallant, M. Morrison, 2007, Journal of medicinal chemistry.

Pyridyl-pyrimidine benzimidazole derivatives as potent, selective, and orally bioavailable inhibitors of Tie-2 kinase.

Xin Huang, Christopher Mohr, Paul Hughes, 2009, Bioorganic & medicinal chemistry letters.

Abstract 1262: BLU-701 is a highly potent, brain-penetrant and WT-sparing next-generation EGFR TKI for the treatment of sensitizing (ex19del, L858R) and C797S resistance mutations in metastatic NSCLC

S. Kazmirski, Ayşegül Özen, K. Hoeflich, 2021, Experimental and Molecular Therapeutics.

Targeting kinases with precision

A. Gardino, C. Lengauer, N. Brooijmans, 2018, Molecular & cellular oncology.

Discovery and optimization of potent and selective imidazopyridine and imidazopyridazine mTOR inhibitors.

T. Bush, A. Cheng, P. Andrews, 2012, Bioorganic & medicinal chemistry letters.

Discovery of potent and highly selective thienopyridine Janus kinase 2 inhibitors.

Xin Huang, Renee Emkey, A. Cheng, 2011, Journal of medicinal chemistry.

Evaluation of PRKACA as a Therapeutic Target for Fibrolamellar Carcinoma

Nicolas Stransky, K. Hoeflich, C. Lengauer, 2022, bioRxiv.

Abstract 791: BLU-285, the first selective inhibitor of PDGFRα D842V and KIT Exon 17 mutants

A. Gardino, C. Lengauer, T. Guzi, 2015 .

Alkynylpyrimidine amide derivatives as potent, selective, and orally active inhibitors of Tie-2 kinase.

David Powers, Paul Hughes, Richard Kendall, 2007, Journal of medicinal chemistry.

First Selective KIT D816V Inhibitor for Patients with Systemic Mastocytosis

A. Gardino, C. Lengauer, T. Guzi, 2014 .

Abstract 21: Selective and potent inhibitors of the mutant B-Raf pathway paradoxically stimulate the MAPK pathway in wild-type B-Raf cells

R. Radinsky, R. Kendall, T. Burgess, 2010 .